Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CV2CoV mRNA Vaccine in Seropositive Adults
NCT05260437Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of raxtozinamaran in coronavirus disease 2019 (COVID-19) (6 cohorts), sponsored by GSK. Primary endpoints: Adverse Events of Special Interest, Serious Adverse Events and 4 more. Started Mar 2022; status: completed.
02
Drugs
raxtozinamaran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05260437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05260437.